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The impact of nephrometry score on partial nephrectomy rates
and survival
Ali Barbaros BAŞESKİOĞLU, Yunus Saim Cavit CAN, Aydın YENİLMEZ, Coşkun KAYA
Aim: To evaluate the utility of the nephrometry score (NS) and its effects on survival using our experiences with renal
tumor data.
Materials and methods: Data from 220 patients who underwent renal tumor surgery between 2002 and 2008 were
analyzed retrospectively. The exclusion criteria were lack of preoperative tomography films or pathological data and loss
of patients for follow-up. Preoperative computed tomography of the patients was evaluated according to the R.E.N.A.L.
NS system at www.nephrometry.com, and low, moderate, and high complexity groups were compared. A cut-off point
of 8 for the NS was determined and patients were grouped. Kaplan-Meier and logistic regression tests were used for
survival analysis.
Results: Seventy patients were included in the study. Of these, 49 (70%) were treated with radical nephrectomy and 21
were treated with partial nephrectomy (30%). Low, moderate, and high complexity scores were calculated in 20 (28.5%),
22 (31.4%), and 28 (40%) of the patients, respectively. Partial nephrectomy surgeries comprised 85% (n = 17) of the
low complexity group and 18.1% (n = 4) of the moderate group. Univariate analysis showed that pathological stage and
complexity group were significant factors indicating survival; pathological stage was the only independent factor.
Conclusion: The NS is an objective method in the evaluation of patients with renal tumors and may be a promising
means of increasing partial nephrectomy rates in moderately complex cases. Although pathological stage, rather than
the NS, is an independent factor for survival, the NS may be a useful preoperative tool.
Key words: Nephrometry, renal tumors, partial nephrectomy, survival

Nefrometri skorunun parsiyel nefrektomi ve sağkalım üzerine etkisi
Amaç: Nefrometri skorunun (NS) kullanılabilirlik ve sağkalım üzerine olan etkisini değerlendirmesi
Yöntem ve gereç: Renal tümor cerrahisi uygulanan 220 hastanın verileri retrospektif olarak analiz edildi. Dışlama
kriteri preoperatif tomografi veya patoloji verilerinin olmaması ve hastanın takip sırasında kaybedilmesiydi. Hastaların
preoperatif bilgisayarlı tomografileri www.nephrometry.com’daki R.E.N.A.L. NS’ye göre değerlendirildi ve düşük, orta,
yüksek kompleks gruplar karşılaştırıldı. NS için kestirim noktası (8) belirlendi ve hastalar gruplandırıldı. Sağkalım
analizleri için Kaplan Meier ve lojistik regresyon testleri kullanıldı.
Bulgular: Çalışmaya 70 hasta alındı. Bunların 49’u (% 70) radikal nefrektomi ve 21’i (% 30) parsiyel nefrektomi ile tedavi
edildi. Düşük, orta ve yüksek komplekslik skorları sırasıyla 20 (% 28,5), 22 (% 31,4) ve 28 (% 40) hasta olarak hesaplandı.
Parsiyel nefrektomi operasyonları düşük komplekslik grubunun % 85’ini (n = 17) ve orta karmaşıklık grubunun %
18.1’ini (n = 4) kapsıyordu. Tek değişkenli analize göre, patolojik evre ve NS sağkalımı gösteren anlamlı faktörler iken;
multivaryant analizde patolojik evre bağımsız olan tek faktördü.
Sonuç: NS renal tümörlü hastaların değerlendirilmesinde objektif bir metottur ve orta komplekslikteki hastalarda PN
oranlarının artması anlamında ümit verici olabilir. NS ile karşılaştırıldığında, patolojik evrenin sağkalım için bağımsız
faktör olmasına rağmen NS yararlı bir preoperatif kriter olabilir.
Anahtar sözcükler: Nefrometri, renal tümör, parsiyel nefrektomi, sağkalım
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Introduction
Detection of organ-confined and incidental renal
cell carcinoma (RCC) has increased with the use of
advanced imaging techniques in the last 2 decades.
The radical nephrectomy (RN), described by Robson
in 1963, has been the gold standard for all renal
masses to improve tumor control (1). Recently, the
partial nephrectomy (PN), the gold standard for
nephron-sparing therapy, was reported to be safe and
to have equivalent oncological results to RN for renal
tumors of less than 4 cm (2). According to tumor
node metastasis staging, PN was also suggested for
pT1b renal tumors in some studies because of its
equivalent cancer control (3). Although nephronsparing surgery (NSS) has favorable oncological
outcomes and advantages for postoperative renal
function (4), it has been performed in only a small
portion of patients with renal neoplasm (5). Despite
the fact that radiological tumor characteristics
can be more important in surveying and choosing
the best treatment modality, only tumor size has
been considered in defined predictive nomograms
and prognostic factors (6). Currently, there are no
published studies with completed external validation
regarding radiological tumor characteristics, which
could be useful in choosing RN, PN, or another
treatment modality.
The nephrometry score (NS), first described by
Kutikov et al., depends on the anatomical features of
renal tumors, which are visible using tomography (7).
The primary end point of this study was to describe
partial nephrectomy rates according to complexity
groups and evaluate whether this scoring system
might be useful in determining the best method of
treatment. Our secondary goal was to identify the
relationship between this scoring system and survival
outcomes.
Materials and methods
Between 2002 and 2008, 220 patients who
underwent RN or PN with solid renal masses were
analyzed retrospectively. Preoperative radiological
documentation and pathological reports were
available for 70 of these patients. Exclusion criteria
632

for the study were lack of preoperative computerized
tomography (CT) films or pathological reports, or
loss of patients for follow-up. All of the preoperative
CTs of the patients were scored according to the
R.E.N.A.L. nephrometry score (R.E.N.A.L. NS, at
www.nephrometry.com). The R.E.N.A.L. NS consists
of the (R)adius (tumor size at maximal diameter),
(E)xophytic/endophytic properties of the tumor, (N)
earness of tumor’s deepest portion to the collecting
system or sinus, (A)nterior (a)/posterior (p)
descriptor, and (L)ocation relative to the polar line.
The suffix h (hilar) is assigned to tumors that abut the
main renal artery or vein. Based on the nephrometry
sum, all of the renal tumors were divided into 3
groups: low (4 to 6 points), moderate (7 to 9 points),
and high (10 to 12 points) complexity lesions (7). An
open approach was taken in all of the cases. All of the
patients were evaluated postoperatively every 3 to 6
months for the first 2 years after the procedure, and
every 6 months thereafter, with physical examination,
chest radiography, abdominal computed tomography,
blood chemistry panel, and, if indicated, radionuclide
bone scanning.
All of the eligible data were collected using SPSS
15.0 software. For disease-specific survival analysis,
the patients were divided into 2 groups according to
the cut-off point found with the receiver operating
curve (lesion complexity score of 4-8 vs. 9-12). As
the known pathological stage is a strong predictor
of survival, all of the preoperative parameters were
evaluated by pathological stage, and pT1 and pT2
were grouped independently from pT3. Clinical
findings suggested as prognostic factors were
grouped as age (<57 vs. ≥57), sex (male vs. female),
tumor side (left vs. right), tumor size (≤7 cm vs. >7
cm), and diagnosis (incidental vs. symptomatic),
and these were included in the univariate analysis.
Significant parameters in the univariate analysis were
reevaluated in the multivariate analysis. KaplanMeier tests were used for the univariate analysis,
while logistic regression analysis was used for the
multivariate analysis. P < 0.05 was accepted as
significant. Complications were not assessed in this
study, but none of the deaths that may affect survival
analysis were related to complications.
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Results
A total of 70 patients, 37 men (52.9%) and 33 women
(47.1%), were included in the study. Mean age at

diagnosis was 56.4 ± 10.6 years. The mean follow-up
time was 57.2 ± 26.9 months. The demographics of
the patients are summarized in Table 1.

Table 1. The demographic data of the patients (* indicates mean ± standard deviation).
Total
Age*
Sex
Side
Pain
Hematuria
Palpable mass
Type of presentation
Localization

Radiological cystic appearance
Radiological size
Operation type
Stage

Pathologic size*
Perirenal fat invasion
Adrenal involvement
Renal vein invasion
Necrosis
Pathologic type

Fuhrman grade

Men
Women
Right
Left
+
+
Symptomatic
Incidental
Upper
Middle
Lower
Diffuse
+
RN
PN
T1
T2
T3
+
+
+
+
Clear cell
Papillary
Collecting duct
Sarcomatoid
Multilocular cystic
Oncocytoma
Chromophobe
Unclassified
1
2
3
4

56.4 ± 10.6
37 (52.8%)
33 (47.1%)
39 (55.7%)
31 (44.2%)
41 (58.5%)
29 (41.4%)
57 (81.4%)
13 (18.5%)
0
38 (54.2%)
32 (45.7%)
17 (24.2%)
24 (34.2%)
28 (40%)
1 (1.4%)
63 (90%)
7 (10%)
6.34 ± 2.68
49 (70%)
21 (30%)
36 (51.4%)
16 (22.8%)
18 (25.7)
6.34 ± 2.84
55 (78.5%)
15 (21.4%)
68 (97.1%)
2 (2.8%)
63 (90%)
7 (10%)
67 (95.7%)
3 (4.2%)
52 (74.2%)
1 (1.4%)
4 (5.7%)
2 (2.8%)
1 (1.4%)
6 (8.5%)
1 (1.4%)
3 (4.2%)
16 (22.8%)
39 (55.7%)
14 (20%)
1 (1.4%)
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Pathological stage and complexity groups
according to the cut-off point were significant in
the univariate disease-specific survival analysis (P =
0.001 and P = 0.043, respectively) (Table 3 and Figure
1a and 1b). Insignificant parameters in the univariate
analysis were age (P = 0.63), sex (P = 0.73), tumor
side (P = 0.58), diagnosis (P = 0.52), and tumor size
(P = 0.12). In the multivariate analysis, pathological
stage was the only independent factor, while the
complexity groups did not reach significance (P =
0.034 vs. P = 0.521).

Low, moderate, and high nephrometry scores
were calculated for 20 (28.5%), 22 (31.4%), and
28 (40%) patients, respectively (Table 2). RN was
performed in 49 cases (70%), and 21 patients were
treated with PN (30%). PN rates were 85% (n = 17)
in the low complexity group and 18.1% (n = 4) in
the moderate group. All of the patients with high
complexity lesions were treated with RN. There was
a shift to lower complexity groups in the total score
when compared with tumor size only. The overall PN
rate was 12.2%.

Table 2. The distribution of the patients according to the NS.
1

2

3

R

19 (27.1%)

22 (31.4%)

29 (41.4%)

E

31 (44.2%)

30 (42.8%)

9 (12.8%)

N

19 (27.1%)

27 (38.5%)

24 (34.2%)

a

p

x

A

33 (47.1%)

34 (48.5%)

3 (4.2%)

L

11 (15.7%)

24 (34.2%)

35 (50%)

Low (4-6)

Moderate (7-9)

High (10-12)

20 (28.5%)

22 (31.4%)

28 (40%)

T

Table 3. The results of significant parameters in the disease-specific survival analysis.

P-value
(Kaplan-Meier)

Pathological stage

Group 1
Group 2
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Standard
deviation

95% confidence
interval

0.001
127.2
35.9

Group A
Group B
Complexity group

Estimate

10.7
8.2

16.2
8.7

Hazard ratio

0.034

6.2

0.521

1.6

106.2-148.3
19.8-51.9

0.041
127.2
66.9

P-value
(Logistic regression)

95.4 -159
49.7-84.1
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Figure. Kaplan-Meier graphics of a) the pathologic stage and b) the NS.

Discussion
In recent years, the detection of renal tumors has
increased to 60% with the greater use of quality
imaging techniques (8). In general, RN has been
performed to increase tumor control because urooncologists have evaluated all of the renal masses,
except angiomyolipomas, as renal cell cancer until
the results of the histopathological analysis are
known. Despite the advantage of tumor control after
RN, the procedure is associated with increased risk
of chronic renal failure and its associated conditions,
such as cardiovascular morbidity, hospitalization,
and death (9,10). The cancer-specific, metastasis-free
survival and the local or distant recurrence rates after
PN and RN have been demonstrated to be similar
(3). The risk of chronic renal failure is less for PN,
and the procedure has a more positive impact on
quality of life (11). The ideal patient for PN has been
defined as a patient with a solitary, exophytic, and
easily resectable tumor of up to 4 cm in diameter,
but few patients fit all of these conditions (12). The
characteristics of aggressive-appearing tumors have
not been defined clearly and tumor size remains
the only preoperative predictive value. However,
the surgical margins, local recurrences, and cancerrelated death rates are not predicted by tumor size
in localized RCC (13,14). Becker et al. (15) proposed
consideration of a tumor’s tomography presentation
and the surgeon’s technical ability, rather than tumor
size, when making decisions about whether PN could
be performed instead of RN (16). However, despite all
of the advantages of PN, there are limitations to the
use of this treatment modality based on tumor size,
tumor location, and the experience of the surgeon.
The NS system described here accounts for
almost all of the anatomical signs that are generally
considered before the procedure. Moreover, it
is easy to use and could be applied during daily
practice. Recent reports have mentioned a similar

cancer-specific survival after PN in appropriate
patients who had larger tumors (14). Results of
another retrospective study showed that in selected
patients with stage T1b-T3N0M0 RCC, PN
provided equivalent intermediate-term oncological
efficacy and superior renal function outcomes
when compared to RN (17). Additionally, excellent
cancer-specific outcomes at 5 and 10 years have been
shown after PN for renal tumors of up to 7 cm (18).
However, oncological safety was less evident in RCC
of greater than 7 cm when PN was performed (19).
The main reason for these limitations was the lack
of a standardized descriptive system to characterize
renal tumor anatomy.
The complications most likely to occur after or
during PN may be predictable using this method.
Urine leakage can be evaluated more accurately when
measuring the tumor depth. The degree of bleeding
may be predictable by scoring polar lines and endo/
exophytic properties. Using parameters similar to
the NS, the preoperative aspects and dimensions
used for an anatomical (PADUA) classification of
renal tumors was developed for prediction of these
complications (20).
The description of PN rates in each complexity
group was the primary end point of this study. Kutikov
et al. published rates of 88%, 84%, and 46.6% for low,
moderate, and high complexity groups, respectively
(7). Our rates were much lower than these overall,
with significant differences for the moderate and high
complexity groups. Our high complexity group was
composed mainly of patients with tumor diameters
greater than 7 cm. We did not think that performing
PN in 46% of these cases would be possible. The data
presented in the study by Kutikov et al. might have
consisted of tumors in solitary kidneys or, based on
Becker’s suggestions, perhaps the group was more
experienced than we were (15). Our overall PN rates
were comparable to those of Hollenbeck et al. (12.2 vs.
635
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9.6, respectively) (5). However, as a self-criticism, this
could be higher due to the use of the NS. We think that
the PN system will be most helpful in patients who
have renal tumors with diameters between 4 and 7 cm.
Another issue, observed in Table 2, is the grouping
of a small subset of patients who fell between the
groups. The number of patients in the R1 column,
which represents tumor size below 4 cm, was 19.
However, the low complexity group contained 20
patients; therefore, 1 patient who had a renal tumor
of greater than 4 cm in diameter was included in the
low complexity group and was much more likely
to receive PN. The same situation occurred with 1
patient in the R3 column who was included in the
moderate complexity group. We found that RN was
performed on the R2 patient who was included in
the low complexity group. We had previously made
our treatment decisions based on tumor size, and
therefore, when we evaluated these findings together,
the use of complexity groups and the NS to determine
the course of treatment was likely to increase elective
PN rates in all of the groups due to the higher PN rates
in the lower complexity groups. All of the patients
included in the low complexity group were eligible
for PN. In addition, patients in the R2 group who
exhibited low complexity were also candidates for
PN. In conclusion, the NS can be useful in treatment
decisions for renal tumors of between 4 and 7 cm or
over 7 cm in size.
Prognostic factors and nomograms are used
to predict the likelihood of cancer in patients
with renal masses. Clinical signs, tumor-related
factors, various laboratory findings, age, and sex are
important prognostic factors in RCC. Independently,
pathological stage, histologic subtype, Fuhrman
grade, and tumor size are the important parameters.
However, factors that have independence on the
multivariate analysis are the most useful and
powerful. Pathological stage has proven to be the
single most important prognostic factor for RCC.
Various molecular markers, such as high levels of
CA-9 and Ki-67, lymph node involvement, and
systemic metastasis, are other factors for poor
survival (21). Several factors were combined for
improving predictive capacity, and the nomogram
created by Lane included factors of age, sex, CT size
of the renal mass, local symptoms at diagnosis, and
636

history of smoking. This method was designed for
use in choosing the best treatment modality (RN
or PN) for renal tumors no larger than 7 cm (22).
According to another study, the treatment modality
decision should not depend on tumor size alone
because small measurement errors in CT size could
cause errors (23). In general, pathologic size is not
the same as CT size, and there has been controversy
about the significance of this difference (24,25). In
another algorithm, the score was based on stage,
size, grade, and necrosis (SSIGN score) to predict
survival (26). The UCLA Integrated Staging System
consisted of pathological stage, Eastern Cooperative
Oncology Group (ECOG) performance status,
Fuhrman grade, and histological subtypes. RCC
histological subtype is an important prognostic
feature; papillary and chromophobe RCCs are less
aggressive than clear cell RCC (22). Another study
by Kattan et al. used size, tumor subtype, stage, and
preoperative symptoms to develop a postoperative
prognostic nomogram that predicted recurrence and
death (27). The centrality index was first described by
Gill et al. (28). Complexity groups, which account for
tumor size and anatomical location, had significance
in univariate analysis; however, the NS was not
an independent factor in our study. Additional
analysis indicated that these nomograms consisted of
multiple independent factors. This was the first study
to evaluate a spectrum including tumor depth, tumor
polarity, and tumor size. Combining these parameters
showed no independently significant variables at
the end of the study. As has been shown previously,
pathological stage was one of the most important
independent prognostic factors for renal tumor
outcome in this study. Depending only on anatomical
signs in imaging is not sufficient to predict survival,
but it is superior to the use of radiological tumor size
alone. We suggest adding complexity groups in place
of tumor size in the nomograms described above to
improve accuracy.
Use of tumor size as a basis for treatment
decisions in RCC can be insufficient and misleading.
In an effort to increase objectivity in determining
which treatment is the better choice, the NS is useful,
although it is not an independent factor indicating
survival. The NS may be effective for increasing
partial nephrectomy rates, especially in patients with
moderately complex lesions.
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